新型高效线粒体解偶联药物MB1-47在T细胞白血病中的治疗作用
该研究在T-ALL细胞及小鼠模型中测试新型线粒体解偶联剂MB1-47,发现其通过破坏线粒体能量和代谢物耗竭抑制增殖并诱导细胞死亡,激活AMPK并抑制mTOR信号,在PDX模型中显著延长生存且无重叠毒性,提示线粒体氧化磷酸化是T-ALL治疗靶点。
要点
- MB1-47通过细胞静止和细胞毒性双重作用抑制T-ALL细胞增殖
- MB1-47急性处理激活AMPK并下调mTOR信号,阻断合成代谢
- MB1-47在PDX和小鼠原发白血病模型中显著延长生存且无重叠毒性
核心结论
- 线粒体氧化磷酸化在T-ALL中起关键作用,MB1-47驱动的线粒体解偶联是治疗T-ALL的新策略。
研究设计与样本
- 在T-ALL细胞系、原代白血病细胞及小鼠模型( murine NOTCH1诱导的原发白血病和人T-ALL患者来源异种移植PDX)中测试MB1-47。
主要发现
- MB1-47处理T-ALL细胞通过细胞静止和细胞毒性作用强烈抑制增殖,导致线粒体能量受损和代谢物耗竭,严重损害核苷酸生物合成。
- MB1-47急性处理原代白血病细胞激活AMPK并下调mTOR信号,阻滞支持白血病细胞存活的合成代谢途径。
- MB1-47在携带鼠源NOTCH1诱导原发白血病或人T-ALL PDX的小鼠中产生强效抗白血病作用,显著延长生存且无重叠毒性。
临床怎么用
- MB1-47作为线粒体解偶联剂,在临床前模型中显示抗T-ALL活性且毒性可耐受,支持进一步开发为T-ALL靶向代谢治疗。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
T-cell acute lymphoblastic leukemia (T-ALL) is an aggressive hematologic malignancy. Despite recent advances in treatments with intensified chemotherapy regimens, relapse rates and associated morbidities remain high. In this context, metabolic dependencies have emerged as a druggable opportunity for the treatment of leukemia. Here, we tested the antileukemic effects of MB1-47, a newly developed mitochondrial uncoupling compound. MB1-47 treatment in T-ALL cells robustly inhibited cell proliferation via both cytostatic and cytotoxic effects as a result of compromised mitochondrial energy and metabolite depletion, which severely impaired nucleotide biosynthesis. Mechanistically, acute treatment with MB1-47 in primary leukemias promoted adenosine monophosphate-activated serine/threonine protein kinase (AMPK) activation and downregulation of mammalian target of rapamycin (mTOR) signaling, stalling anabolic pathways that support leukemic cell survival. Indeed, MB1-47 treatment in mice harboring either murine NOTCH1-induced primary leukemias or human T-ALL patient-derived xenografts (PDXs) led to potent antileukemic effects with a significant extension in survival without overlapping toxicities. Overall, our findings demonstrate a critical role for mitochondrial oxidative phosphorylation in T-ALL and uncover MB1-47-driven mitochondrial uncoupling as a novel therapeutic strategy for the treatment of this disease.
引用
- da Silva-Diz V, Cao B, Lancho O, et al. A novel and highly effective mitochondrial uncoupling drug in T-cell leukemia. Blood. 2021. PMID: 33876224. doi:10.1182/blood.2020008955
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。